Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
EZH2 inhibitor |
| gptkbp:administeredBy |
oral
|
| gptkbp:CASNumber |
1346574-57-9
|
| gptkbp:clinicalTrialPhase |
gptkb:Phase_I
|
| gptkbp:developedBy |
GlaxoSmithKline
|
| gptkbp:hasMolecularFormula |
C23H22N4O2
|
| https://www.w3.org/2000/01/rdf-schema#label |
GSK-126
|
| gptkbp:mechanismOfAction |
inhibits histone methyltransferase activity
|
| gptkbp:molecularWeight |
386.45 g/mol
|
| gptkbp:potentialIndication |
leukemia
solid tumors |
| gptkbp:synonym |
gptkb:GSK126
|
| gptkbp:target |
EZH2 enzyme
|
| gptkbp:usedIn |
cancer research
|
| gptkbp:bfsParent |
gptkb:GSK126
|
| gptkbp:bfsLayer |
8
|